HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement NDI Notification Guidance Cruel To Firms On Animal Testing

This article was originally published in The Rose Sheet

Executive Summary

CFSAN’s latest draft guidance for NDI notifications does little to address the supplement industry’s concerns, and the “worst” aspect is a recommendation to test ingredients on animals when historical use data is not available, says a New Hope Network analyst.

You may also be interested in...



Industry Eyes NDI Notification Common Ground With Gottlieb-Led FDA

CHPA and CRN look forward to working with FDA to develop a path for the identification of pre-DSHEA ingredients, but say the FDA’s revised draft guidance for new dietary ingredient notifications still hampers innovation.

Memebox DTC Whiz To Expand Platform For Korean, In-House Brands

Korean beauty brand-focused Memebox reaches more than 3.3m users with its direct-to-consumer platform, including rapidly growing segments in China and the US. The startup, which just received $66m in new venture funding, leverages social media and celebrity partnerships to drive engagement and sales, while speedily introducing branded product lines of its own.

US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

Topics

Latest News
UsernamePublicRestriction

Register

RS108579

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel